Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(23 sites)
China
Peking University First Hospital, Beijing, Beijing Municipality Peking University People's Hospital, Beijing, Beijing Municipality Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, Chongqing Municipality Fujian Medical University Union Hospital, Fuzhou, Fujian Guangzhou First Municipal People's Hospital, Guangzhou, Guangdong